TARGA MANAGEMENT TEAM

Gary D. Aronson, M.B.A., J.D.
Chief Executive Officer
Member, Board of Directors

• Targa Chief Executive Officer and Co-Founder
• 18 Years experience in biotechnology start-ups & financing
• Work related to 10 Biotechnology start-ups and early-stage companies
• Co-founder & President, DepoTech Corp. sustained release injectable drug delivery company
• Broad biopharma experience including biotechnology research reagents, anti-cancer drugs, pain drugs, drug delivery systems, rational drug design, drug development, human gene therapy and regenerative medicine

In a prior position as president of DepoTech Corp., Mr. Aronson had overall responsibility for supervising the pre-clinical and clinical development of several new sustained-release formulations in a number of therapeutic fields, including DepoCyte™, an anti-cancer drug now on the market, DepoMorphine™ a pain medication whose NDA has now been submitted for U.S. FDA approval and DepoBupivacaine™, a pain medications currently in advanced human clinical trials, and several other formulations in various stages of development.

Randy Berholtz, J.D.

Randy Berholtz is Vice President, Business Development for ACON Laboratories, a Chinese-based medical device and diagnostics manufacturer. Prior to that position he was Chief Operating Officer for IngleWood Ventures, a San Diego based life sciences venture capital fund and prior to that was Senior Director, Business Development for Nanogen, Inc., a San Diego genetic products company. He is an Advisory Board member of the Keck Graduate Institute of Applied Life Sciences at the Claremont Colleges and is a member of the Life Science Angels of Menlo Park. He received a BA summa cum laude from Cornell University, a masters degree from Oxford University where he was a Rhodes Scholar and a law degree from the Yale Law School.

ABOUT US:  Markets | Corporate Strategy | Team| News

HOME - TECHNOLOGIES - PRODUCT CANDIDATES - SERVICES - ABOUT US - CONTACT